Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk

Approximately half of all patients with type 2 diabetes (T2D) develop a certain degree of renal impairment. In many of them, chronic kidney disease (CKD) progresses over time, eventually leading to end-stage k...

Source: Cardiovascular Diabetology - November 22, 2020 Category: Cardiology Authors: Francesco Giorgino, Jiten Vora, Peter Fenici and Anna Solini Tags: Review Source Type: research